146 related articles for article (PubMed ID: 11337567)
1. Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer.
Murray A; Simms MS; Scholfield DP; Vincent RM; Denton G; Bishop MC; Price MR; Perkins AC
J Nucl Med; 2001 May; 42(5):726-32. PubMed ID: 11337567
[TBL] [Abstract][Full Text] [Related]
2. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595.
Hughes OD; Bishop MC; Perkins AC; Wastie ML; Denton G; Price MR; Frier M; Denley H; Rutherford R; Schubiger PA
J Clin Oncol; 2000 Jan; 18(2):363-70. PubMed ID: 10637251
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer.
Hughes OD; Bishop MC; Perkins AC; Frier M; Price MR; Denton G; Smith A; Rutherford R; Schubiger PA
Eur J Nucl Med; 1997 Apr; 24(4):439-43. PubMed ID: 9096097
[TBL] [Abstract][Full Text] [Related]
4. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies.
Griffiths GL; Goldenberg DM; Knapp FF; Callahan AP; Chang CH; Hansen HJ
Cancer Res; 1991 Sep; 51(17):4594-602. PubMed ID: 1873804
[TBL] [Abstract][Full Text] [Related]
5. Endovascular beta irradiation for prevention of restenosis using solution radioisotopes: pharmacologic and dosimetric properties of rhenium-188 compounds.
Knapp FF; Guhlke S; Beets AL; Lin WY; Stabin M; Amols H; Weinberger J
Cardiovasc Radiat Med; 1999; 1(1):86-97. PubMed ID: 11272362
[TBL] [Abstract][Full Text] [Related]
6. Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors--a review of radiolabeling characteristics, quality control and in vitro stability studies.
Iznaga-Escobar N
Appl Radiat Isot; 2001 Mar; 54(3):399-406. PubMed ID: 11214873
[TBL] [Abstract][Full Text] [Related]
7. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
Russell PJ; Plomley J; Shon IH; O'Grady H; Pearce N
Cell Biophys; 1993; 22(1-3):27-47. PubMed ID: 7889541
[TBL] [Abstract][Full Text] [Related]
11. Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.
Frier M
Mini Rev Med Chem; 2004 Jan; 4(1):61-8. PubMed ID: 14754444
[TBL] [Abstract][Full Text] [Related]
12. Intravesical administration of radiolabelled tumour-associated monoclonal antibody in bladder cancer.
Syrigos KN; Khawaja M; Krausz T; Williams G; Epenetos AA
Acta Oncol; 1999; 38(3):379-82. PubMed ID: 10380831
[TBL] [Abstract][Full Text] [Related]
13. Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. A model for intravesical radioimmunotherapy.
Russell PJ; Ho Shon I; Boniface GR; Izard ME; Philips J; Raghavan D; Walker KZ
Urol Res; 1991; 19(4):207-13. PubMed ID: 1926654
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
[TBL] [Abstract][Full Text] [Related]
15. 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology.
Iznaga-Escobar N
Nucl Med Biol; 1998 Jul; 25(5):441-7. PubMed ID: 9720661
[TBL] [Abstract][Full Text] [Related]
16. [Production and therapeutic use of rhenium-186, 188--the future of radionuclides].
Vucina J; Han R
Med Pregl; 2003; 56(7-8):362-5. PubMed ID: 14587255
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site.
Ogawa K; Kawashima H; Kinuya S; Shiba K; Onoguchi M; Kimura H; Hashimoto K; Odani A; Saji H
Ann Nucl Med; 2009 Dec; 23(10):843-8. PubMed ID: 19921351
[TBL] [Abstract][Full Text] [Related]
19. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
20. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
